Literature DB >> 18655424

Foetomaternal outcome of pregnancy with cardiac disease.

Tayyiba Wasim1, Wasim Amer, Ashraf Majrroh, Saqib Siddiq.   

Abstract

INTRODUCTION: To study the prevalence of cardiac disease in pregnancy and to assess the foetomaternal outcomes.
METHODS: It was a 5 year descriptive study. All pregnant females with a known or newly diagnosed congenital or acquired cardiac lesion on echo cardiography were included in the study.
RESULTS: There were 17,056 births during the study period, of whom 160 were cardiac patients giving a prevalence of 1%. Out of these 36% patients were diagnosed to have cardiac disease during current pregnancy. Acquired valvular heart lesions were found in 132 (82%) patients with mitral stenosis being the commonest (55%), others were congenital. Of the group, 43% patients were in class III &amp; IV according to NYHA. Majority delivered vaginally and only 29% had c/section, 9% had therapeutic termination of pregnancy and 45% babies were low birth weight. Ten babies expired. Maternal mortality was low (3.8%), while 55(35%) had obstetric complications. Poor functional class (III &amp; IV) was the key determinant of adverse footomaternal outcome (p<0.0001).
CONCLUSION: The good results of this study can be attrihuted to the team efforts of between obstetricians, cardiologists and patients. Adverse foetomaternal outcome was related to poor functional class III and IV of NYHA.

Entities:  

Mesh:

Year:  2008        PMID: 18655424

Source DB:  PubMed          Journal:  J Pak Med Assoc        ISSN: 0030-9982            Impact factor:   0.781


  2 in total

Review 1.  Is vaginal delivery or caesarean section the safer mode of delivery in patients with adult congenital heart disease?

Authors:  Victoria Asfour; Michael O Murphy; Rizwan Attia
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-07

2.  Fetomaternal outcome of pregnancy with Mitral stenosis.

Authors:  Nazia Ahmed; Hafeeza Kausar; Lubna Ali
Journal:  Pak J Med Sci       Date:  2015       Impact factor: 1.088

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.